Vertex (VRTX) and Molecular Templates (MTEM) Establish Pact to Discover, Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Vertex (VRTX) and Molecular Templates (MTEM) Establish Pact to Discover, Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

November 18, 2019 7:00 AM EST

-Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales-

BOSTON and AUSTIN, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; Molecular Templates or MTEM) today announced that the two companies have entered into a strategic research collaboration to discover and develop novel targeted conditioning regimens that may enhance the hematopoietic stem cell transplant process, including transplants conducted as part of treatment with ex vivo CRISPR/Cas9 gene editing therapies such as CTX001.  CTX001 is currently... More